Cargando…

FOXP3(+) regulatory T cells use heparanase to access IL-2 bound to ECM in inflamed tissues

FOXP3(+) regulatory T cells (Treg) depend on exogenous IL-2 for their survival and function, but circulating levels of IL-2 are low, making it unclear how Treg access this critical resource in vivo. Here, we show that Treg use heparanase (HPSE) to access IL-2 sequestered by heparan sulfate (HS) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Hunter A., Koliesnik, Ievgen, Kaber, Gernot, Reid, Jacqueline K., Nagy, Nadine, Barlow, Graham, Falk, Ben A., Medina, Carlos O., Hargil, Aviv, Vlodavsky, Israel, Li, Jin-Ping, Pérez-Cruz, Magdiel, Tang, Sai-Wen, Meyer, Everett H., Wrenshall, Lucile E., Lord, James D., Garcia, K. Christopher, Palmer, Theo D., Steinman, Lawrence, Nepom, Gerald T., Wight, Thomas N., Bollyky, Paul L., Kuipers, Hedwich F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002643/
https://www.ncbi.nlm.nih.gov/pubmed/36909599
http://dx.doi.org/10.1101/2023.02.26.529772
Descripción
Sumario:FOXP3(+) regulatory T cells (Treg) depend on exogenous IL-2 for their survival and function, but circulating levels of IL-2 are low, making it unclear how Treg access this critical resource in vivo. Here, we show that Treg use heparanase (HPSE) to access IL-2 sequestered by heparan sulfate (HS) within the extracellular matrix (ECM) of inflamed central nervous system tissue. HPSE expression distinguishes human and murine Treg from conventional T cells and is regulated by the availability of IL-2. HPSE(−/−) Treg have impaired stability and function in vivo, including the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Conversely, endowing Treg with HPSE enhances their ability to access HS-sequestered IL-2 and their tolerogenic function in vivo. Together, these data identify novel roles for HPSE and the ECM in immune tolerance, providing new avenues for improving Treg-based therapy of autoimmunity.